FOLH1 and prostate carcinoma: Researchers engineered PSMA-targeted CAR-NK cells, which demonstrated specificity and cytotoxicity against the PSMA-positive prostate cancer cell line LNCaP, effectively impeding tumor growth and enhancing survival in mouse models [105].